Increased osteopontin expression following renal ablation is attenuated by angiotensin type 1 receptor antagonism

Zemin Cao1, Alison Cox, Fabrice Bonnet

  • 1Department of Medicine, University of Melbourne, Austin & Repatriation Medical Center, Heidelberg West, Vic., Australia. cao@austin.unimelb.edu.au

Experimental Nephrology
|January 23, 2002
PubMed

Insights

Osteopontin, a protein linked to kidney injury, is upregulated in rats with progressive renal damage. Treatment with irbesartan, an angiotensin type 1 receptor antagonist, reduced osteopontin levels and improved kidney function.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pathology

Background:

  • Osteopontin is an extracellular matrix protein implicated in renal injury.
  • Its role in progressive renal damage requires further investigation.

Purpose of the Study:

  • To investigate renal osteopontin expression in a rat model of progressive renal injury after subtotal nephrectomy (STNx).
  • To evaluate the effect of the angiotensin type 1 (AT1) receptor antagonist irbesartan on osteopontin expression and renal pathology.

Main Methods:

  • Subtotal nephrectomy (STNx) or sham operation in Sprague-Dawley rats.
  • Administration of irbesartan (15 mg/g) or no treatment to STNx rats for 12 weeks.
  • In situ hybridization and double immunohistochemical staining to assess osteopontin mRNA, monocyte/macrophage infiltration, and cellular proliferation.

Main Results:

  • STNx induced significant upregulation of osteopontin mRNA in injured renal tubules.
  • Increased osteopontin expression correlated with monocyte/macrophage infiltration and cellular proliferation.
  • Irbesartan treatment inhibited osteopontin upregulation, attenuated renal dysfunction and pathology, and reduced inflammation and proliferation.

Conclusions:

  • Osteopontin is upregulated in progressive renal injury following STNx in rats.
  • AT1 receptor antagonism with irbesartan effectively reduces osteopontin expression and ameliorates renal damage.

Related Concept Videos

Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...